journal article·2021-06-30

Nanostructured Non-Newtonian Drug Delivery Barrier Prevents Postoperative Intrapericardial Adhesions

Xichi Wang, Zongtao Liu, Diego A. Sandoval-Salaiza, Samson Afewerki, Mildred G. Jimenez-Rodriguez, Lorena Sanchez-Melgar, Gabriela Güemes-Aguilar, David G. Gonzalez-Sanchez, Oscar Noble, Cecilia Lerma, Roberto Parra-Saldivar, Dario R. Lemos, Guillermo A. Llamas-Esperon, Jiawei Shi, Li Li, Anderson O. Lobo, Andres A. Fuentes-Baldemar, Joseph V. Bonventre, Nianguo Dong, Guillermo U. Ruiz-Esparza

ACS Applied Materials & Interfaces· Volume 13· Issue 25
Publisher page

Abstract

With the increasing volume of cardiovascular surgeries and the rising adoption rate of new methodologies that serve as a bridge to cardiac transplantation and that require multiple surgical interventions, the formation of postoperative intrapericardial adhesions has become a challenging problem that limits future surgical procedures, causes serious complications, and increases medical costs. To prevent this pathology, we developed a nanotechnology-based self-healing drug delivery hydrogel barrier composed of silicate nanodisks and polyethylene glycol with the ability to coat the epicardial surface of the heart without friction and locally deliver dexamethasone, an anti-inflammatory drug. After the fabrication of the hydrogel, mechanical characterization and responses to shear, strain, and recovery were analyzed, confirming its shear-thinning and self-healing properties. This behavior allowed its facile injection (5.75 ± 0.15 to 22.01 ± 0.95 N) and subsequent mechanical recovery. The encapsulation of dexamethasone within the hydrogel system was confirmed by 1 H NMR, and controlled release for 5 days was observed. In vitro, limited cellular adhesion to the hydrogel surface was achieved, and its anti-inflammatory properties were confirmed, as downregulation of ICAM-1 and VCAM-1 was observed in TNF-α activated endothelial cells. In vivo, 1 week after administration of the hydrogel to a rabbit model of intrapericardial injury, superior efficacy was observed when compared to a commercial adhesion barrier, as histological and immunohistochemical examination revealed reduced adhesion formation and minimal immune infiltration of CD3+ lymphocytes and CD68+ macrophages, as well as NF-κβ downregulation. We presented a novel nanostructured drug delivery hydrogel system with unique mechanical and biological properties that act synergistically to prevent cellular infiltration while providing local immunomodulation to protect the intrapericardial space after a surgical intervention.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Transportation Planning and Optimization · Traffic Prediction and Management Techniques · Human Mobility and Location-Based Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States

Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

Renal Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States

Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

School of Engineering and Science, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64849, Mexico

Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

School of Medicine and Health Science, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64849, Mexico

Department of Interventional Cardiology, Hospital Cardiológica, Aguascalientes, Aguascalientes 20230, Mexico

LIMAV—Interdisciplinary Laboratory for Advanced Materials, BioMatLab group, Material Science and Engineering Graduate Program, UFPI- Federal University of Piauí, Teresina, Piauí 64049−550, Brazil

Funding

Ministry of Science and Technology of the People's Republic of China · Brigham and Women's Hospital · Harvard Medical School · Massachusetts Institute of Technology · Huazhong University of Science and Technology · Tecnol?gico de Monterrey · Department of Cardiovascular Surgery, Huazhong University of Science and Technology

References (55)

Show source-provided references
1. 10.1186/s42490-019-0005-010.1186/s42490-019-0005-0 ↗
2. 10.1016/j.jtcvs.2010.07.08610.1016/j.jtcvs.2010.07.086 ↗
3. 10.1186/1471-2482-11-1310.1186/1471-2482-11-13 ↗
4. Anyanwu A. C. · 2011 · 241
5. 10.1016/j.jtcvs.2007.08.06010.1016/j.jtcvs.2007.08.060 ↗
6. 10.1016/j.pcad.2016.11.00110.1016/j.pcad.2016.11.001 ↗
7. 10.1016/j.athoracsur.2012.11.02010.1016/j.athoracsur.2012.11.020 ↗
8. 10.1016/j.tice.2016.11.00410.1016/j.tice.2016.11.004 ↗
9. 10.1016/s0015-0282(02)04569-710.1016/s0015-0282(02)04569-7 ↗
10. Lorini F. L. · 2019 · 11710.1007/978-3-319-99891-6_10 ↗
11. Tissot C. · 2020 · 50310.1007/978-3-030-21870-6_45 ↗
12. 10.1046/j.1365-2168.2000.01394.x10.1046/j.1365-2168.2000.01394.x ↗
13. 10.1016/s1010-7940(01)00698-410.1016/s1010-7940(01)00698-4 ↗
14. 10.1016/j.progpolymsci.2014.10.00410.1016/j.progpolymsci.2014.10.004 ↗
15. 10.1038/s41551-019-0442-z10.1038/s41551-019-0442-z ↗
16. 10.1007/s00268-007-9242-910.1007/s00268-007-9242-9 ↗
17. 10.1093/humrep/der13510.1093/humrep/der135 ↗
18. 10.1039/c8sm01965g10.1039/c8sm01965g ↗
19. 10.1053/j.jvca.2011.03.00210.1053/j.jvca.2011.03.002 ↗
20. 10.1039/C8BM00469B10.1039/C8BM00469B ↗
21. 10.1039/b919449p10.1039/b919449p ↗
22. 10.1002/pat.351410.1002/pat.3514 ↗
23. 10.1016/j.ijpharm.2017.01.00110.1016/j.ijpharm.2017.01.001 ↗
24. 10.1016/j.actbio.2010.09.01510.1016/j.actbio.2010.09.015 ↗
25. Papanicolaou G. C. · 2011 · 310.1533/9780857090430.1.3 ↗
26. 10.1098/rsif.2005.006510.1098/rsif.2005.0065 ↗
27. 10.1152/japplphysiol.00823.200210.1152/japplphysiol.00823.2002 ↗
28. 10.1152/ajpheart.1977.232.6.H55310.1152/ajpheart.1977.232.6.H553 ↗
29. 10.1093/eurheartj/ehu35310.1093/eurheartj/ehu353 ↗
30. 10.1586/erc.10.2810.1586/erc.10.28 ↗
31. 10.1016/j.nano.2017.04.01610.1016/j.nano.2017.04.016 ↗
32. 10.1038/s41598-017-08771-810.1038/s41598-017-08771-8 ↗
33. Garg A. · Pharmaceut. Technol. N. Am. · 2002 · 26 · 84
34. 10.1039/c7ra04419d10.1039/c7ra04419d ↗
35. 10.1016/j.fbio.2020.10059610.1016/j.fbio.2020.100596 ↗
36. 10.1021/am302130b10.1021/am302130b ↗
37. 10.1039/c3ra43217c10.1039/c3ra43217c ↗
38. 10.1016/j.ejpb.2016.08.01510.1016/j.ejpb.2016.08.015 ↗
39. 10.1016/j.clay.2007.09.00210.1016/j.clay.2007.09.002 ↗
40. 10.1006/exer.1997.042910.1006/exer.1997.0429 ↗
41. 10.1016/j.ijpharm.2017.01.00110.1016/j.ijpharm.2017.01.001 ↗
42. 10.1002/adma.20130103410.1002/adma.201301034 ↗
43. 10.1111/anae.1461010.1111/anae.14610 ↗
44. 10.1016/j.athoracsur.2012.11.02010.1016/j.athoracsur.2012.11.020 ↗
45. 10.1016/j.actbio.2017.08.00210.1016/j.actbio.2017.08.002 ↗
46. 10.3390/ma905039710.3390/ma9050397 ↗
47. 10.1681/asn.201408084010.1681/asn.2014080840 ↗
48. 10.1016/j.atherosclerosis.2011.04.02710.1016/j.atherosclerosis.2011.04.027 ↗
49. 10.1148/radiol.201918212210.1148/radiol.2019182122 ↗
50. 10.1016/j.actbio.2018.10.02210.1016/j.actbio.2018.10.022 ↗
51. 10.1590/abd1806-4841.2016474110.1590/abd1806-4841.20164741 ↗
52. 10.1186/1749-7922-8-610.1186/1749-7922-8-6 ↗
53. 10.3109/08820139.2016.115781410.3109/08820139.2016.1157814 ↗
54. 10.1007/s00404-011-2097-110.1007/s00404-011-2097-1 ↗
55. 10.1016/j.addr.2019.02.00610.1016/j.addr.2019.02.006 ↗